Black Diamond Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2021. For the quarter, the company reported loss from operations of $34,715,000 against $15,028,000 a year ago. Net loss was $34,351,000 or $0.95 per basic and diluted share against $14,571,000 or $0.41 per basic and diluted share a year ago. For the six months, the company reported loss from operations of $65,428,000 against $27,907,000 a year ago. Net loss was $64,652,000 or $1.79 per basic and diluted share against $26,716,000 or $0.92 per basic and diluted share a year ago.